Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

src="http://content.prnewswire.com/designimages/widetable-release.JPG" style="border:0px" alt="Click to view news release full screen">  

Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial

   

-- Two-Year Results from Independent 'All-Comers' Study of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®-- Data Show that the Differences in the Two Stents Increase at Two Years-- In the Study, Patients Receiving XIENCE V Had a 77 Percent Lower Rate of Stent Thrombosis (Blood Clot) than TAXUS Liberte at Two Years

ABBOTT PARK, Ill., Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data were presented today from the investigator-initiated COMPARE trial of 1,800 real-world patients involving Abbott's (NYSE: ABT) market-leading XIENCE V® Everolimus Eluting Coronary Stent System and the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System (TAXUS). The results from COMPARE at two years were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

For the endpoint of major adverse cardiac events (MACE) at two years, which is a composite of all death, non-fatal heart attack (myocardial infarction or MI) and target vessel revascularization (TVR), XIENCE V showed a 34 percent lower incidence of MACE compared to TAXUS (9.0 percent for XIENCE V vs. 13.7 percent for TAXUS, p-value=0.0016). The composite secondary endpoint of cardiac death, non-fatal MI and target lesion revascularization (TLR) resulted in a 35 percent lower incidence for XIENCE V compared t
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today ... Officer, will present at two upcoming investor conferences in ... on November 16th at 10:30 am at The Pierre ... Conference on November 29 at 11:50 am at The ...
... 2011 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2011. (Logo:   http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ) ... were $6.0 million, 3% higher than sales of $5.8 ... to increases in sales of the Company,s medical device ...
Cached Medicine Technology:Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 2Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 2Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 4Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 5
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced ... introduced this summer at the treatment center in Puerto Vallarta, Mexico. , The ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... insufficient scrotal support and protection against dribbled urine and sweat. "In order to ... Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... that pelvic imaging using computed tomography (CT) examinations are ... and eliminating this exam can significantly reduce a patient,s ... the pelvis during CT pulmonary angiography does not improve ... author for this study. He asserts, "Using CT venography ...
... FOR DETERMINING SOURCE OF ACUTE SHORTNESS OF BREATH ... replace standard chest x-ray as the first choice of ... source of acute dyspnea is needed. Italian researchers studied ... strong agreement between the results of chest ultrasonography and ...
... Inhaled Beta-agonists Increase Survival Over Anticholinergics ... agents are commonly prescribed to manage chronic obstructive ... to decrease exacerbations and hospitalizations and improve COPD ... mortality. However, it is not known which therapy ...
... HealthDay Reporter , MONDAY, May 2 (HealthDay News) -- The ... than the brains of normally developing children, and the difference ... The finding is a follow-up to earlier research that found ... of similarly aged normally developing kids, researchers said. ...
... Reporter , MONDAY, May 2 (HealthDay News) -- Kids who ... up getting injured more often, new research suggests. ... pursuit were almost twice as likely to get hurt as ... Neeru Jayanthi, medical director of primary care sports medicine at ...
... May 2 (HealthDay News) -- American workers forced to travel ... study suggests. A team of U.S. researchers found that ... are at higher risk for cardiovascular disease than "light" travelers who ... The team at Columbia University,s Mailman School of Public Health analyzed ...
Cached Medicine News:Health News:Chest journal news briefs, May 2011 issue 2Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3Health News:Brains of Autistic Kids Still Larger at Age 4, 5 2Health News:Brains of Autistic Kids Still Larger at Age 4, 5 3Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 2Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 3Health News:Frequent Business Travel Tough on the Heart, Study Finds 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: